Clinical Trial Update: Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating tigecycline for serious infections caused by vancomycin-resistant Enterococcus bacteria or Methicillin-resistant Staphylococcus aureu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Staphylococcus Aureus Infection
• Vancomycin-resistant Enterococcus Infection

Drugs mentioned

• Tigecycline (tigecycline)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Gram-Positive Bacterial Infections, Staphylococcus Infections | Phase 3 | Status: COMPLETED